Evaluation of the Safety and Efficacy of Corifollitropin Alfa Combined with GnRH Agonist Triggering in Oocyte Donation Cycles. A Prospective Longitudinal Study

Overview

Journal JBRA Assist Reprod

Specialty Reproductive Medicine

Date 2020 Jun 4

PMID 32489086

Citations 2

Authors

Ioannis Tsakiridis

Robert Najdecki

Petroula Tatsi

Evi Timotheou

Kallirhoe Kalinderi

Georgios Michos

Andriana Virgiliou

Hakan Yarali

Apostolos Athanasiadis

Evangelos G Papanikolaou

Affiliations

Soon will be listed here.

Abstract

Objective: In order to help make the dream of parenthood come true for oocyte acceptors, it is essential that the procedure is not dangerous or unpleasant for oocyte donors. The aim of this study was to identify differences in safety, efficacy and patient acceptability between a traditional stimulation antagonist protocol with recombinant-FSH (rFSH) with hCG-triggering, compared with an innovative antagonist protocol with corifollitropin alfa (Elonva®) plus GnRH agonist triggering in oocyte donors.

Methods: A prospective longitudinal study was conducted at an in vitro fertilization center in Greece. The same eighty donors underwent two consecutive antagonist stimulation schemes. Primary outcomes were patient satisfaction (scored by a questionnaire) and delivery rate per donor. Secondary outcomes were mean number of cumulus-oocyte-complexes, metaphase II (MII) oocytes and ovarian hyperstimulation syndrome (OHSS) rate.

Results: Donors reported better adherence and less discomfort with the corifollitropin alpha + GnRH agonist-triggering protocol (p<0.001). No significant differences were identified in the clinical pregnancy rate per donor (p=0.13), the delivery rates, the number of oocytes (p=0.35), the number of MII oocytes (p=0.50) and the number of transferred embryos, between the two protocols. However, the luteal phase duration was significantly shorter (p<0.001) in the corifollitropin alpha + GnRH agonist-triggering protocol. Moreover, three cases of moderate OHSS (3.75%) were identified after hCG triggering, whereas no case of OHSS occurred after GnRH agonist ovulation induction (p=0.25).

Conclusion: The use of corifollitropin alpha combined with a GnRH agonist for triggering is a safe, effective and acceptable protocol for oocyte donors.

Citing Articles

Oral follicle-stimulating hormone receptor agonist affects granulosa cells differently than recombinant human FSH.

Guner J, Monsivais D, Yu H, Stossi F, Johnson H, Gibbons W Fertil Steril. 2023; 120(5):1061-1070.

PMID: 37532169 PMC: 10659100. DOI: 10.1016/j.fertnstert.2023.07.024.

Agonist triggering in oocyte donation programs-Mini review.

Najdecki R, Michos G, Peitsidis N, Timotheou E, Chartomatsidou T, Kakanis S Front Endocrinol (Lausanne). 2022; 13:838236.

PMID: 36093096 PMC: 9462512. DOI: 10.3389/fendo.2022.838236.

References

Bodri D, Guillen J, Galindo A, Mataro D, Pujol A, Coll O . Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. Fertil Steril. 2008; 91(2):365-71. DOI: 10.1016/j.fertnstert.2007.11.049. View

Galindo A, Bodri D, Guillen J, Colodron M, Vernaeve V, Coll O . Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial. Gynecol Endocrinol. 2009; 25(1):60-6. DOI: 10.1080/09513590802404013. View

Griesinger G, Diedrich K, Devroey P, Kolibianakis E . GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update. 2005; 12(2):159-68. DOI: 10.1093/humupd/dmi045. View

Humaidan P, Papanikolaou E, Kyrou D, Alsbjerg B, Polyzos N, Devroey P . The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. Reprod Biomed Online. 2011; 24(2):134-41. DOI: 10.1016/j.rbmo.2011.11.001. View

Lutjen P, Trounson A, Leeton J, Findlay J, Wood C, Renou P . The establishment and maintenance of pregnancy using in vitro fertilization and embryo donation in a patient with primary ovarian failure. Nature. 1984; 307(5947):174-5. DOI: 10.1038/307174a0. View

Acevedo B, Gomez-Palomares J, Ricciarelli E, Hernandez E . Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil Steril. 2006; 86(6):1682-7. DOI: 10.1016/j.fertnstert.2006.05.049. View

Pacchiarotti A, Selman H, Valeri C, Napoletano S, Sbracia M, Antonini G . Ovarian Stimulation Protocol in IVF: An Up-to-Date Review of the Literature. Curr Pharm Biotechnol. 2016; 17(4):303-15. DOI: 10.2174/1389201017666160118103147. View

Fauser B, Alper M, Ledger W, Schoolcraft W, Zandvliet A, Mannaerts B . Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reprod Biomed Online. 2011; 22 Suppl 1:S23-31. DOI: 10.1016/S1472-6483(11)60006-0. View

Devroey P, Boostanfar R, Koper N, Mannaerts B, Ijzerman-Boon P, Fauser B . A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod. 2009; 24(12):3063-72. PMC: 2777786. DOI: 10.1093/humrep/dep291. View

10.

Hernandez E, Gomez-Palomares J, Ricciarelli E . No room for cancellation, coasting, or ovarian hyperstimulation syndrome in oocyte donation cycles. Fertil Steril. 2008; 91(4 Suppl):1358-61. DOI: 10.1016/j.fertnstert.2008.03.077. View

11.

Farrag A, Costantini A, Manna C, Grimaldi G . Recombinant HCG for triggering ovulation increases the rate of mature oocytes in women treated for ICSI. J Assist Reprod Genet. 2008; 25(9-10):461-6. PMC: 2582096. DOI: 10.1007/s10815-008-9262-x. View

12.

Shapiro B, Daneshmand S, Garner F, Aguirre M, Ross R . Comparison of human chorionic gonadotropin and gonadotropin-releasing hormone agonist for final oocyte maturation in oocyte donor cycles. Fertil Steril. 2007; 88(1):237-9. DOI: 10.1016/j.fertnstert.2006.11.069. View

13.

Fatemi H, Polyzos N, Van Vaerenbergh I, Bourgain C, Blockeel C, Alsbjerg B . Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril. 2013; 100(3):742-7. DOI: 10.1016/j.fertnstert.2013.05.028. View

14.

Jayaprakasan K, Herbert M, Moody E, Stewart J, Murdoch A . Estimating the risks of ovarian hyperstimulation syndrome (OHSS): implications for egg donation for research. Hum Fertil (Camb). 2007; 10(3):183-7. DOI: 10.1080/14647270601021743. View

15.

Humaidan P, Kol S, Papanikolaou E . GnRH agonist for triggering of final oocyte maturation: time for a change of practice?. Hum Reprod Update. 2011; 17(4):510-24. DOI: 10.1093/humupd/dmr008. View

16.

Youssef M, Abdelmoty H, Ahmed M, Elmohamady M . GnRH agonist for final oocyte maturation in GnRH antagonist co-treated IVF/ICSI treatment cycles: Systematic review and meta-analysis. J Adv Res. 2015; 6(3):341-9. PMC: 4522577. DOI: 10.1016/j.jare.2015.01.005. View

17.

. A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Hum Reprod. 2008; 23(11):2484-92. DOI: 10.1093/humrep/den288. View

18.

Croxtall J, McKeage K . Corifollitropin alfa: a review of its use in controlled ovarian stimulation for assisted reproduction. BioDrugs. 2011; 25(4):243-54. DOI: 10.2165/11206890-000000000-00000. View

19.

Requena A, Cruz M, Collado D, Izquierdo A, Ballesteros A, Munoz M . Evaluation of the degree of satisfaction in oocyte donors using sustained-release FSH corifollitropin α. Reprod Biomed Online. 2013; 26(3):253-9. DOI: 10.1016/j.rbmo.2012.11.015. View

20.

Al-Inany H, Youssef M, Ayeleke R, Brown J, Lam W, Broekmans F . Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016; 4:CD001750. PMC: 8626739. DOI: 10.1002/14651858.CD001750.pub4. View